乳腺癌Ki-67和CyclinD1在预测及评估新辅助化疗疗效中的价值  

Expression of Ki-67 and CyclinD1 in breast cancer patients and their predictive and evaluation value in the efficacy of neoadjuvant chemotherapy

作　　者：刘润奇 叶建森 徐天鸣[1] 钟慕仪[1] LIU Runqi;YE Jianshen;XU Tianming;ZHONG Muyi(Dongguan People's Hospital,Dongguan 523000,Guangdong,China)

机构地区：[1]东莞市人民医院,广东东莞523000

出　　处：《西部医学》2022年第5期753-756,760,共5页Medical Journal of West China

基　　金：东莞市社会科技发展(一般)项目(201950715001849)。

摘　　要：目的探讨乳腺癌Ki-67和CyclinD1在预测及评估新辅助化疗疗效中的价值。方法选取2019年7月~2020年12月我院的60例临床Ⅱ-Ⅲ期的乳腺癌患者,以Miller-Payne系统评价新辅助化疗疗效,通过免疫组化检测化疗前后Ki-67、CyclinD1的表达,分析化疗前后Ki-67、CyclinD1表达的改变及与化疗疗效的关系。结果病理缓解组化疗前Ki-67的表达水平高于非病理缓解组,差异有统计学意义(P<0.05);化疗后Ki-67的表达水平较化疗前下降,差异有统计学意义(P<0.05);化疗后Ki-67的明显下降与病理缓解具有相关性(r=0.392,P<0.05)。病理缓解组化疗前CyclinD1的表达水平与非病理缓解组无明显差异(P>0.05),化疗后CyclinD1的表达水平与化疗前无明显差异(P>0.05)。化疗前CyclinD1的表达与Ki-67呈正相关(r=0.334,P<0.05)。结论Ki-67具有预测及评估乳腺癌新辅助化疗疗效的作用。CyclinD1的表达与新辅助化疗疗效无明显关系。Objective To investigate the value of Ki-67 and CyclinD1 in breast cancer in predicting and evaluating the response after neoadjuvant chemotherapy. Methods This study includes 60 patients with stage Ⅱ and Ⅲ breast cancer between 2019-7 and 2020-12. The response was assessed according to Miller-Payne system. The pre-and post-neoadjuvant chemotherapy Ki-67 and CyclinD1 were detected by immunohistochemistry. The changes, as well as the relationship with response, of Ki-67 and CyclinD1 were analyzed. Results The pre-neoadjuvant chemotherapy expression level of Ki-67 in the group with pathological response was significantly higher than with non pathological response(P<0.05). Ki-67 expression was decreased after neoadjuvant chemotherapy(P<0.05). The marked decrease of Ki-67 expression was significantly correlated with pathological response. There was no significant difference in the pre-neoadjuvant chemotherapy expression level of CyclinD1 between the group with pathological response and non pathological response. Also, the significant difference in the expression level of CyclinD1 between pre-neoadjuvant and post-neoadjuvant chemotherapy was not found. The pre-neoadjuvant chemotherapy expression level of CyclinD1 was significantly correlated with Ki-67. However, the pre-neoadjuvant chemotherapy expression level of CyclinD1 was significantly correlated with Ki-67. Conclusion Ki-67 in breast cancer showed value in predicting and evaluating the response after neoadjuvant chemotherapy. There was no relationship between the expression of CyclinD1 and response.

关 键 词：乳腺癌 细胞周期蛋白D1 增殖细胞核抗原 新辅助化疗 疗效 

分 类 号：R736.3[医药卫生—肿瘤]